Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.31 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4006614 | 0.78 | PFKFB3 (0.47) | PFKFB3CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL27758748 | 0.78 | PFKFB3 (0.47) | PFKFB3CA12CA1CA2CA9 | |
| SCHEMBL8029209 | 0.71 | F10 (0.42) | PFKFB3CA12CA1CA2CA9 | |
| SCHEMBL9198944 | 0.68 | L3MBTL1 (0.34) | PFKFB3CA12CA1CA2CA9 | |
| SCHEMBL3098780 | 0.68 | APP (0.61) | MMP2MMP9 | |
| SCHEMBL27679133 | 0.64 | CCR1 (0.47) | PFKFB3PFKFB4CA12CA1CA2 | |
| SCHEMBL4198555 | 0.64 | KDM4E (0.63) | PFKFB3PFKFB4MEN1KMT2A | |
| SCHEMBL391587 | 0.64 | PFKFB3 (0.47) | PFKFB3CA12CA1CA2CA9 | |
| SCHEMBL1416134 | 0.63 | L3MBTL1 (0.46) | CA2KMT2A | |
| SCHEMBL2672963 | 0.63 | MEN1 (0.33) | PTGS2PFKFB3PFKFB4CCR5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | PTGS2 1459/4885PFKFB3 3051/4885PFKFB4 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.